NCT04649359 · OUTCOME

Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb · Source last updated 2026-05-19

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)

What was measured

MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-12
denom Units Selected: Participants
description: MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria.
reporting Status: NOT_POSTED
time Frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)
title: Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice